IGF2BP1 and ovarian cancer: EdU assays showed that the proportion of new cells in the CACNA1G-AS1 overexpression group obviously increased (p < 0.01), while this proportion correspondingly decreased after IGF2BP1 and FTH1 inhibition in ovarian cancer cells (p < 0.01, Figs. 5B and 5C).